FAQ
The questions, answered plainly.
01 What does AGEMICA actually do? +
We design peptide therapies and vaccines using AI, then validate them in ex vivo human cell models. Our scientific work is preclinical.
02 Are these drugs available to patients? +
No. Everything described is preclinical. We make no claim of clinical benefit in humans until human trials advance through proper gates.
03 How is your AI different from other drug-discovery AI? +
We are designed for combinations of approved or clinically characterized drugs against multi-omics tumor signatures. Most drug-discovery AI optimizes single molecules; we optimize ranked combinations and peptide candidates.
04 What does "100% cancer cell death" mean? +
It is an ex vivo readout in selected human cancer cell models, in defined assay conditions. It is not a claim of human clinical efficacy.
05 Why peptides? +
Peptides sit between small molecules and biologics - programmable, manufacturable, and immunogenically tunable. They translate AI predictions into synthesizable molecules in days, not months.
06 What is the XPRIZE involvement? +
AGEMICA is an XPRIZE Healthspan semifinalist in a $101M competition to demonstrate functional age reversal in older adults.
07 Where is the team based? +
Stanford and Cambridge. Operations are distributed; our wet-lab work runs through partnered facilities.
08 Who is funding the work? +
- R42 Group
- Willamette Ventures
09 How do I work with you? +
Email ronjon.nag@agemica.com with a one-paragraph description of fit. We respond to every serious inquiry.
10 How do I follow your progress? +
Subscribe to our research updates. We publish milestones - including the ones we miss.
11 What is your relationship to longevity startups? +
AGEMICA is a peptide platform. Many longevity claims rest on supplements or single small molecules; ours rests on AI-ranked combinations validated in human cell models.
12 Do you publish? +
Yes. Methodology summaries are available on request, and we are pursuing peer-reviewed publication on platform components.